ArticleESC heart failure2018

Rationale and design of a multicentre, randomized, placebo-controlled trial of mirabegron, a Beta3-adrenergic receptor agonist on left ventricular mass and diastolic function in patients with structural heart disease Beta3-left ventricular hypertrophy (Beta3-LVH).

Anne-Catherine Pouleur et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.